Edition:
United States

Yield10 Bioscience Inc (YTEN.OQ)

YTEN.OQ on NASDAQ Stock Exchange Capital Market

1.50USD
22 Jun 2018
Change (% chg)

$-0.05 (-3.23%)
Prev Close
$1.55
Open
$1.50
Day's High
$1.58
Day's Low
$1.48
Volume
23,690
Avg. Vol
89,841
52-wk High
$8.67
52-wk Low
$1.38

Latest Key Developments (Source: Significant Developments)

Yield10 Bioscience Reports Q4 Loss Per Share Of $0.99
Thursday, 8 Mar 2018 04:04pm EST 

March 8 (Reuters) - Yield10 Bioscience Inc ::YIELD10 BIOSCIENCE ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.99 FROM CONTINUING OPERATIONS.Q4 REVENUE $100,000 VERSUS $300,000.COMPANY ANTICIPATES NET CASH USAGE OF APPROXIMATELY $8.5 MILLION TO $9.0 MILLION DURING 2018.  Full Article

Yield10 Bioscience Announces Pricing Of $12.6 Mln Public Offering
Tuesday, 19 Dec 2017 08:43am EST 

Dec 19 (Reuters) - Yield10 Bioscience Inc ::YIELD10 BIOSCIENCE ANNOUNCES PRICING OF $12.6 MILLION PUBLIC OFFERING.YIELD10 BIOSCIENCE INC - OFFERING HAS 3.8 MILLION CLASS A UNITS, PRICED AT $2.25 PER UNIT, AND 3,987 CLASS B UNITS, PRICED AT $1,000 PER UNIT.  Full Article

Yield10 Bioscience Grants Research License To Monsanto To Evaluate Two Novel Yield Traits In Soybean
Monday, 11 Dec 2017 08:00am EST 

Dec 11 (Reuters) - Monsanto Co ::YIELD10 BIOSCIENCE INC - ‍GRANTED A NON-EXCLUSIVE RESEARCH LICENSE TO MONSANTO COMPANY TO EVALUATE ITS NOVEL C3003 AND C3004 YIELD TRAITS IN SOYBEAN​.YIELD10 BIOSCIENCE INC - ‍UNDER LICENSE, MONSANTO PLANS TO RESEARCH BOTH TRAITS WITHIN ITS SOYBEAN PIPELINE AS A STRATEGY TO IMPROVE PLANT YIELDS​.  Full Article

Yield10 Bioscience posts Q3 loss $0.59/shr from continuing operations
Thursday, 9 Nov 2017 04:03pm EST 

Nov 9 (Reuters) - Yield10 Bioscience Inc :Yield10 Bioscience announces third quarter 2017 financial results.Q3 loss per share $0.59 from continuing operations.Q3 revenue $200,000 versus $500,000.Yield10 Bioscience Inc - expects to use about $8.0 million to $8.5 million in cash for FY 2017, including anticipated payments for restructuring costs​.Yield10 Bioscience Inc - expects current cash resources will be sufficient to fund operations & meet obligations into Q1 2018​.Yield10 - "the ‍company's present capital resources raise substantial doubt, however, about company's ability to continue as a going concern"​.  Full Article

‍Yield10 Bioscience obtains confirmation of nonregulated status from USDA-APHIS for its genome-edited Camelina line​
Tuesday, 5 Sep 2017 08:35am EDT 

Sept 5 (Reuters) - Yield10 Bioscience Inc ::‍Yield10 bioscience obtains confirmation of nonregulated status from USDA-APHIS for its genome-edited Camelina line​.  Full Article

Yield10 Bioscience says selling security holders‍​ may resell up to 570,784 shares of company
Friday, 18 Aug 2017 02:17pm EDT 

Aug 18 (Reuters) - Yield10 Bioscience Inc ::Files prospectus related to resale of upto 570,784 shares of co's stock issuable upon exercise of certain outstanding warrants‍​.Co not selling any securities under prospectus, will not receive any proceeds from sale of securities by selling security holders‍​.  Full Article

Yield10 Bioscience Q2 loss per share $0.96 from continuing operations
Thursday, 10 Aug 2017 04:05pm EDT 

Aug 10 (Reuters) - Yield10 Bioscience Inc :Yield10 Bioscience announces second quarter 2017 financial results.Q2 loss per share $0.96 from continuing operations.Q2 revenue $300,000 versus $200,000.Yield10 Bioscience- ‍progress with the studies keeps us on track to begin reporting out additional yield data on c3003 in oilseed crops starting in q4 2017​.Yield10 Bioscience Inc - ‍company ended q2 with $3.0 million in unrestricted cash and cash equivalents​.Yield10 Bioscience - anticipates will use approximately $8.0 to $8.5 million of cash during 2017, including anticipated payments for restructuring costs​.Yield10 Bioscience Inc - ‍present capital resources are not sufficient to fund its planned operations for a twelve month period​.Yield10 Bioscience Inc - ‍present capital resources raise substantial doubt about company's ability to continue as a going concern​.  Full Article

Yield10 Bioscience announces pricing of $2.3 mln registered direct offering
Monday, 3 Jul 2017 08:30am EDT 

July 3 (Reuters) - Yield10 Bioscience Inc :Yield10 Bioscience announces pricing of $2.3 million registered direct offering.Yield10 Bioscience - Entered into securities purchase agreement with investors for purchase,sale of 570,784 shares of common stock at price of $4/share.Yield10 Bioscience - Issue warrants in private placement to purchase upto equivalent number of shares of common stock with exercise price of $5.04/share.  Full Article

Yield10 Bioscience announces 1-for-10 reverse stock split
Friday, 26 May 2017 08:30am EDT 

May 26 (Reuters) - Yield10 Bioscience Inc :Yield10 Bioscience announces 1-for-10 reverse stock split.Yield10 Bioscience Inc says company's common stock will begin trading on a split-adjusted basis on Tuesday, May 30, 2017.  Full Article

Yield10 Bioscience announces Q1 revenue $300,000
Thursday, 11 May 2017 04:05pm EDT 

May 11 (Reuters) - Yield10 Bioscience Inc :Yield10 Bioscience announces first quarter 2017 financial results.Q1 loss per share $0.07 from continuing operations.Q1 revenue $300,000 versus $200,000.  Full Article

BRIEF-Yield10 Bioscience Reports Q1 Loss Per Share $0.24

* YIELD10 BIOSCIENCE ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS